Get the Stockscreener App
9.61
3.11%
0.29
After Hours:
9.95
0.34
+3.54%
Cybin Inc stock is traded at $9.61, with a volume of 391.85K.
It is up +3.11% in the last 24 hours and down -13.89% over the past month.
Cybin Inc., a biotechnology company, focuses on developing psychedelic therapeutics to treat various psychiatric and neurological conditions. The company operates through two segments, Serenity Life and Cybin U.S., and Natures Journey. The Serenity Life and Cybin U.S. segment engages in the research and development of psychedelic pharmaceutical products. The Natures Journey segment focuses on non-psychedelic medicinal mushroom nutraceutical products. It develops CYB001, a drug candidate that is in phase IIa/b for major depressive disorder; CYB003, a deuterated tryptamine preclinical program to treat alcohol use disorder; CYB004, a deuterated tryptamine preclinical program for therapy resistant psychiatric disorder; and CYB005, a phenethylamine preclinical program for psychiatry and neurology. The company offers its products through various form factors, such as capsules, powders, and effervescent tablets. Cybin Inc. is headquartered in Toronto, Canada.
See More
Previous Close:
$9.32
Open:
$9.28
24h Volume:
391.85K
Relative Volume:
1.09
Market Cap:
$192.13M
Revenue:
-
Net Income/Loss:
$-52.07M
P/E Ratio:
-49.56
EPS:
-0.1939
Net Cash Flow:
$-44.93M
1W Performance:
-1.74%
1M Performance:
-13.89%
6M Performance:
-5.14%
1Y Performance:
-35.16%
1-Day Range:
$9.11
$9.67
1-Week Range:
$9.11
$10.06
52-Week Range:
$6.50
$19.85
Cybin Inc Stock (CYBN) Company Profile
Name
Cybin Inc
Sector
Industry
Phone
908 764 8385
Address
100 King Street West, Suite 5600, Toronto
Compare CYBN with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
CYBN
Cybin Inc
|
9.61 | 192.13M | 0 | -52.07M | -44.93M | -0.2077 |
|
VRTX
Vertex Pharmaceuticals Inc
|
397.27 | 102.31B | 10.63B | -479.80M | -1.35B | -1.99 |
|
REGN
Regeneron Pharmaceuticals Inc
|
701.85 | 77.13B | 13.85B | 4.65B | 3.32B | 40.41 |
|
ARGX
Argen X Se Adr
|
623.82 | 37.30B | 1.86B | -40.29M | -1.28B | -0.85 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
245.44 | 31.66B | 2.09B | -332.26M | 16.06M | -2.62 |
|
BNTX
Biontech Se Adr
|
113.08 | 27.11B | 3.30B | -501.07M | 1.03B | -2.1146 |
Cybin Inc Stock (CYBN) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Nov-19-21 | Downgrade | Maxim Group | Buy → Hold |
Cybin Inc Stock (CYBN) Latest News
Objective long/short (CYBN) Report - Stock Traders Daily
Cybin (FRA:R7E) Total Inventories : €0.00 Mil (As of Sep. 2024) - GuruFocus.com
Facet Life Sciences Partners with Cybin to Advance Mental Health Therapies - MSN
Cybin Reveals Promising Results in Depression Treatment - TipRanks
Cybin's Breakthrough Clinical Data Shows 100% Response Rate in Depression Treatment Study - StockTitan
Cybin Announces Poster Presentations at the 2024 American College of Neuropsychopharmacology Annual Meeting, Including CYB003 12-Month Efficacy Results - Yahoo Finance
(CYBN) Investment Report - Stock Traders Daily
PEAK6 Investments LLC Sells 420,512 Shares of Cybin Inc. (NYSE:CYBN) - MarketBeat
Cybin Stock In Focus On MDD Treatment's 'Breakthrough’ Efficacy: Retail Turns Extremely Bullish - MSN
Cybin to Participate in Water Tower Research Fireside Chat on December 11, 2024 - Chatham-Kent This Week
Cybin to Discuss Breakthrough Treatments at Fireside Chat - TipRanks
TANG CAPITAL MANAGEMENT LLC Increases Stake in Cybin Inc - GuruFocus.com
Psychedelic Drugs Market Growth in Future Scope 2024-2031 | - openPR
Cybin (FRA:R7E) 3-Year EPS without NRI Growth Rate : 6.10% (As of Sep. 2024) - GuruFocus.com
Cybin (FRA:R7E) 50-Day SMA : €9.05 (As of Nov. 30, 2024) - GuruFocus.com
Cybin (OTCMKTS:CYBN) Stock Price Down 4.3%What's Next? - MarketBeat
FDA's Psychedelic Reckoning - Life Science Leader Magazine
Cybin (STU:R7E) Earnings Yield (Joel Greenblatt) % : -151.52% (As of Sep. 2024) - GuruFocus.com
Cybin Inc. Advances in Mental Health Treatments - TipRanks
Cybin (STU:R7E) Change In Receivables : €-1.00 Mil (TTM As of Sep. 2024) - GuruFocus.com
What is Bloom Burton's Estimate for Cybin FY2025 Earnings? - MarketBeat
HC Wainwright Brokers Decrease Earnings Estimates for Cybin - MarketBeat
Cybin launches new program phase to treat Major Depressive Disorder - MSN
Breakthrough Therapy Shows Promising Long-Term Results for Depression - Streetwise Reports
Cybin’s Breakthrough: Psychedelic Depression Drug CYB003 Sustains 12-Month Symptom Remission in Major Depressive Disorder - geneonline
H.C. Wainwright reiterates Buy on Cybin stock, sees strong potential for CYB003 in MDD - Investing.com
Cybin reports sustained depression treatment effects By Investing.com - Investing.com Canada
Cybin (NYSE:CYBN) Receives Buy Rating from HC Wainwright - MarketBeat
Cybin Reports Positive Phase 2 Data for CYB003 - The Dales Report
Cybin’s CYB003 Shows Promising Results for Depression - TipRanks
Cybin reports sustained depression treatment effects - Investing.com
Cybin Reports Positive Phase 2 Data for CYB003, Demonstrating Breakthrough 12-Month Efficacy in Treating Major Depressive Disorder - Business Wire
Cybin posts second-quarter loss widens as clinical trials advance - Green Market Report
Canaccord Genuity Group Lowers Cybin (NYSE:CYBN) Price Target to $86.00 - MarketBeat
Cybin to Present 12-Month Phase 2 Data for CYB003 in Major Depressive Disorder on November 18, 2024 - BioSpace
Cybin to Present Promising CYB003 Study Results - TipRanks
Cybin to Showcase Promising Depression Treatment Progress - TipRanks
CYBNCybin Inc. Latest Stock News & Market Updates - StockTitan
Cybin Inc (CYBN-NE) QuotePress Release - The Globe and Mail
Cybin launches new program phase to treat Major Depressive Disorder | 2024-11-13 | Investing News - Stockhouse Publishing
Cybin’s Phase 3 Trials and Financial Update - TipRanks
Can Canada’s psychedelic drug developers shake off the sector’s bad trip? - The Globe and Mail
Cybin Initiates PARADIGM: A Multinational Pivotal Phase 3 Program Evaluating CYB003 for the Adjunctive Treatment of Major Depressive Disorder and Reports Second Quarter Financial Results - StreetInsider.com
Cybin Inc. Begins Phase 3 Trials, Betting Big On CYB003 To Treat Depression - Benzinga
What might RFK Jr’s psychedelic strategy look like? - Proactive Investors USA
Cybin Faces Key Data Readouts For Major Depressive Disorder, Generalized Anxiety Disorder - RTTNews
Learn to Evaluate (CYBN) using the Charts - Stock Traders Daily
Cybin Inc. (NYSE:CYBN) Stake Lowered by Rosalind Advisors Inc. - MarketBeat
Cybin (OTCMKTS:CYBN) Trading Up 0.2%Here's What Happened - MarketBeat
Cybin, Inc.Why Compass Pathways Is No Compass for Cybin's Progression Prospects - Smartkarma
PDS Planning Inc Sells 885,540 Shares of Cybin Inc. (NYSE:CYBN) - MarketBeat
Cybin Inc Stock (CYBN) Financials Data
Revenue
Net Income
Cash Flow
EPS
2.88%
2.65%
Cap:
|
Volume (24h):